Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR3 S249C FGFR3 V555M |
Therapy | Infigratinib |
Indication/Tumor Type | urinary bladder cancer |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 S249C FGFR3 V555M | urinary bladder cancer | resistant | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, a bladder cancer cell line harboring FGFR3 S249C and expressing FGFR3 V555M was resistant to Truseltiq (infigratinib) in culture (PMID: 38437671). | 38437671 |
PubMed Id | Reference Title | Details |
---|---|---|
(38437671) | The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations. | Full reference... |